These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
304 related articles for article (PubMed ID: 32650419)
21. Interleukin-6 induces VEGF secretion from prostate cancer cells in a manner independent of androgen receptor activation. Ishii K; Sasaki T; Iguchi K; Kajiwara S; Kato M; Kanda H; Hirokawa Y; Arima K; Mizokami A; Sugimura Y Prostate; 2018 Aug; 78(11):849-856. PubMed ID: 29707793 [TBL] [Abstract][Full Text] [Related]
22. Castration induces up-regulation of intratumoral androgen biosynthesis and androgen receptor expression in an orthotopic VCaP human prostate cancer xenograft model. Knuuttila M; Yatkin E; Kallio J; Savolainen S; Laajala TD; Aittokallio T; Oksala R; Häkkinen M; Keski-Rahkonen P; Auriola S; Poutanen M; Mäkelä S Am J Pathol; 2014 Aug; 184(8):2163-73. PubMed ID: 24949550 [TBL] [Abstract][Full Text] [Related]
23. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models. Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373 [TBL] [Abstract][Full Text] [Related]
24. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer. Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197 [TBL] [Abstract][Full Text] [Related]
25. Androgen receptor cofactors in prostate cancer: potential therapeutic targets of castration-resistant prostate cancer. Shiota M; Yokomizo A; Fujimoto N; Naito S Curr Cancer Drug Targets; 2011 Sep; 11(7):870-81. PubMed ID: 21762076 [TBL] [Abstract][Full Text] [Related]
26. Therapeutic targeting of the androgen receptor (AR) and AR variants in prostate cancer. Narayanan R Asian J Urol; 2020 Jul; 7(3):271-283. PubMed ID: 32742927 [TBL] [Abstract][Full Text] [Related]
27. Transcription of Nrdp1 by the androgen receptor is regulated by nuclear filamin A in prostate cancer. Savoy RM; Chen L; Siddiqui S; Melgoza FU; Durbin-Johnson B; Drake C; Jathal MK; Bose S; Steele TM; Mooso BA; D'Abronzo LS; Fry WH; Carraway KL; Mudryj M; Ghosh PM Endocr Relat Cancer; 2015 Jun; 22(3):369-86. PubMed ID: 25759396 [TBL] [Abstract][Full Text] [Related]
28. Investigational therapies targeting the androgen signaling axis and the androgen receptor and in prostate cancer - recent developments and future directions. Isaacsson Velho P; Carducci MA Expert Opin Investig Drugs; 2018 Oct; 27(10):811-822. PubMed ID: 30118330 [TBL] [Abstract][Full Text] [Related]
29. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens. Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455 [TBL] [Abstract][Full Text] [Related]
30. Androgen receptor: what we know and what we expect in castration-resistant prostate cancer. Cai Z; Chen W; Zhang J; Li H Int Urol Nephrol; 2018 Oct; 50(10):1753-1764. PubMed ID: 30128923 [TBL] [Abstract][Full Text] [Related]
31. Inhibition of androgen receptor transactivation function by adenovirus type 12 E1A undermines prostate cancer cell survival. Li D; Tian G; Wang J; Zhao LY; Co O; Underill ZC; Mymryk JS; Claessens F; Dehm SM; Daaka Y; Liao D Prostate; 2018 Nov; 78(15):1140-1156. PubMed ID: 30009471 [TBL] [Abstract][Full Text] [Related]
32. Interplay Between SOX9, Wnt/β-Catenin and Androgen Receptor Signaling in Castration-Resistant Prostate Cancer. Khurana N; Sikka SC Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31027362 [TBL] [Abstract][Full Text] [Related]
33. The interplay between AR, EGF receptor and MMP-9 signaling pathways in invasive prostate cancer. Mandel A; Larsson P; Sarwar M; Semenas J; Syed Khaja AS; Persson JL Mol Med; 2018 Jun; 24(1):34. PubMed ID: 30134822 [TBL] [Abstract][Full Text] [Related]
34. The Androgen Receptor and Its Crosstalk With the Src Kinase During Castrate-Resistant Prostate Cancer Progression. Gao L; Han B; Dong X Front Oncol; 2022; 12():905398. PubMed ID: 35832549 [TBL] [Abstract][Full Text] [Related]
35. Molecular and cellular mechanisms of castration resistant prostate cancer. Huang Y; Jiang X; Liang X; Jiang G Oncol Lett; 2018 May; 15(5):6063-6076. PubMed ID: 29616091 [TBL] [Abstract][Full Text] [Related]
36. Androgen receptor antagonists for prostate cancer therapy. Helsen C; Van den Broeck T; Voet A; Prekovic S; Van Poppel H; Joniau S; Claessens F Endocr Relat Cancer; 2014 Aug; 21(4):T105-18. PubMed ID: 24639562 [TBL] [Abstract][Full Text] [Related]
37. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer. Thamilselvan V; Menon M; Thamilselvan S Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552 [TBL] [Abstract][Full Text] [Related]
38. Androgen Receptor-Dependent Mechanisms Mediating Drug Resistance in Prostate Cancer. Ehsani M; David FO; Baniahmad A Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33810413 [TBL] [Abstract][Full Text] [Related]
39. Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer. Han W; Gao S; Barrett D; Ahmed M; Han D; Macoska JA; He HH; Cai C Oncogene; 2018 Feb; 37(6):710-721. PubMed ID: 29059155 [TBL] [Abstract][Full Text] [Related]
40. Estrogen induces androgen-repressed SOX4 expression to promote progression of prostate cancer cells. Yang M; Wang J; Wang L; Shen C; Su B; Qi M; Hu J; Gao W; Tan W; Han B Prostate; 2015 Sep; 75(13):1363-75. PubMed ID: 26015225 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]